Quick Answer
Celldex Therapeutics, Inc. reported Research And Development Expense of $245.07 million for the year ending 2025.
- Celldex Therapeutics, Inc. showed an increase of +49.8% in Research And Development Expense from 2024 to 2025.
- This data is from Celldex Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on February 25, 2026.
- XBRL data for this metric is available from 2009 to 2025 (17 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2010: $7.26 million | Q3 2010: $7.22 million | Q1 2011: $6.85 million | Q2 2011: $7.17 million | Q3 2011: $8.59 million | Q1 2012: $10.77 million | Q2 2012: $11.11 million | Q3 2012: $11.77 million | Q1 2013: $14.09 million | Q2 2013: $15.09 million | Q3 2013: $20.42 million | Q1 2014: $27.07 million | Q2 2014: $24.10 million | Q3 2014: $26.19 million | Q1 2015: $25.13 million | Q2 2015: $26.49 million | Q3 2015: $24.66 million | Q1 2016: $27.45 million | Q2 2016: $25.71 million | Q3 2016: $25.01 million | Q1 2017: $25.79 million | Q2 2017: $25.00 million | Q3 2017: $21.92 million | Q1 2018: $21.88 million | Q2 2018: $21.45 million | Q3 2018: $11.92 million | Q1 2019: $11.15 million | Q2 2019: $10.08 million | Q3 2019: $11.10 million | Q1 2020: $11.70 million | Q2 2020: $9.71 million | Q3 2020: $10.71 million | Q1 2021: $12.72 million | Q2 2021: $12.36 million | Q3 2021: $13.56 million | Q1 2022: $17.06 million | Q2 2022: $20.73 million | Q3 2022: $21.57 million | Q1 2023: $26.80 million | Q2 2023: $26.25 million | Q3 2023: $34.54 million | Q1 2024: $31.66 million | Q2 2024: $39.69 million | Q3 2024: $45.26 million | Q1 2025: $52.61 million | Q2 2025: $54.20 million | Q3 2025: $62.93 million.
- Over the full 17 years of available data (2009 to 2025), Celldex Therapeutics, Inc.'s Research And Development Expense has grown by 836.5%.
- Historical annual values: Fiscal year 2025: $245.07 million | Fiscal year 2024: $163.55 million | Fiscal year 2023: $118.01 million | Fiscal year 2022: $82.26 million | Fiscal year 2021: $53.31 million | Fiscal year 2020: $42.53 million | Fiscal year 2019: $42.67 million | Fiscal year 2018: $66.45 million | Fiscal year 2017: $96.17 million | Fiscal year 2016: $102.73 million | Fiscal year 2015: $100.17 million | Fiscal year 2014: $104.38 million | Fiscal year 2013: $67.40 million | Fiscal year 2012: $47.40 million | Fiscal year 2011: $32.44 million | Fiscal year 2010: $27.65 million | Fiscal year 2009: $26.17 million.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: